DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $650,524 | +1.9% | 2,622 | -1.4% | 0.46% | +1.1% |
| Q2 2023 | $638,581 | -25.2% | 2,660 | -21.5% | 0.45% | -28.0% |
| Q1 2023 | $854,167 | -4.4% | 3,389 | +0.7% | 0.62% | -10.6% |
| Q4 2022 | $893,764 | +17.4% | 3,367 | +14.3% | 0.70% | +12.2% |
| Q3 2022 | $761,000 | +1.9% | 2,947 | 0.0% | 0.62% | +8.7% |
| Q2 2022 | $747,000 | -13.4% | 2,947 | +0.2% | 0.57% | +0.5% |
| Q1 2022 | $863,000 | -13.3% | 2,942 | -2.7% | 0.57% | -11.9% |
| Q4 2021 | $995,000 | +8.5% | 3,024 | +0.4% | 0.65% | +12.9% |
| Q3 2021 | $917,000 | +17.3% | 3,013 | +3.3% | 0.57% | +21.9% |
| Q2 2021 | $782,000 | +22.2% | 2,916 | +2.6% | 0.47% | +11.1% |
| Q1 2021 | $640,000 | +1.3% | 2,843 | -0.2% | 0.42% | -7.0% |
| Q4 2020 | $632,000 | +6.2% | 2,848 | +8.0% | 0.46% | -4.8% |
| Q3 2020 | $595,000 | +14.4% | 2,637 | +2.4% | 0.48% | +17.2% |
| Q2 2020 | $520,000 | +28.7% | 2,575 | -12.0% | 0.41% | +2.0% |
| Q1 2020 | $404,000 | -30.5% | 2,926 | -22.7% | 0.40% | -15.1% |
| Q4 2019 | $581,000 | +3.0% | 3,786 | -3.1% | 0.47% | -22.0% |
| Q3 2019 | $564,000 | – | 3,906 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |